



Supported by:



Funded by the
European Union



Exploring associations between Mpox-related health outcomes and HIV status

Nicolò Girometti

56 Dean Street
Chelsea and Westminster Hospital NHS Foundation Trust

In compliance with the Conflict of Interest Policies, the European AIDS Clinical Society (EACS) requires the following disclosure from the presenters:

NICOLÓ GIROMETTI

Research Support:

Speaker's Bureau:

Board Member/Advisory Panel:

VERDI

Viiv Healthcare

Gilead, Viiv Healthcare



Purpose :

- To explore associations in
 - clinical presentation
 - Mpox-related complications
 - medical management outcomes

according to HIV status in individuals with Mpox

Methods :

- Individuals with **PCR-confirmed Mpox** diagnosed between **May – December 2022** at three large sexual health providers part of Chelsea and Westminster Hospital were included
- Secondary routine data (demographics, medical history, clinical presentation and management) were collected from electronic patient records
- χ^2 and Mann-Whitney U tests were used to explore associations in the proportions of clinical outcomes and HIV status for categorical and continuous variables, respectively.

Results :



- **857** individuals included in the study
(23% of all UK cases, 35% of London cases)


Demographics

- ✓ median age **36 years** (IQR 31-43)
- ✓ **29%** people with HIV
 - of which **95%** on **ART** and **90%** with **viral load < 50 cp/mL**
- ✓ **39%** UK-born
- ✓ **97%** men having sex with men (MSM)
- ✓ **85%** of people without HIV on PrEP


Mpox clinical presentation

Results :

Skin lesions at peak (number), n = 857*



“Prodromal” symptoms, n = 857*



* No differences were found according to HIV status

Mpox clinical presentation

Results :

>3 anatomical sites with skin lesions

Oral mucosa

Limbs


Body

Perianus

Genitalia


Not on genitalia or perianus

Overall (n=857)
PLWH (n=249)
People without HIV (n=608)



Clinical complications in people with Mpox *


Results :



* No differences were found according to HIV status

Clinical complications in people with Mpox


Results :



CD4 count > 350/mm³

CD4 count < 350/mm³


PLWH (n=128)



$p = 0.01$



Additional medical management in people with Mpox

Results :




Additional medical management in people with Mpox

Results :




Concomitant STI rates in people with Mpox

Results :



Total people who were offered STI screening (n=745/857, 87%)




Conclusions :



No differences according to HIV status in:

- hospitalization rates
- medical complications
- adjunctive medical management



A **CD4 count <350/mm³** was associated to


- higher rate of complications
- increased requirement for medical interventions



Mpox is associated with


- high rates of complications (46%)
- frequent concomitant STIs (28%)

Conclusions :



No differences according to HIV status in:

- hospitalization rates
- medical complications
- adjunctive medical management



A **CD4 count <350/mm³** was associated to

- higher rate of complications
- increased requirement for medical interventions



Mpox is associated with

- high rates of complications (46%)
- frequent concomitant STIs (28%)

Mpox is **RESOURCE INTENSIVE** for sexual health clinics and attention to prevention (vaccination!) is **KEY**



THANK YOU

Special thanks to **Dr Martina Zeitler** and the other co-authors
(**Ruth Byrne, Margherita Bracchi, Rachael Jones, Gary Whitlock,**
Gurmit Jagjit Singh, Diarmuid Nugent, Victoria Tittle and **Marta Boffito**)

Big thank you to our wonderful teams at
56 Dean Street, 10 Hammersmith Broadway and **John Hunter Clinic**
and to the **patients** who allowed us to produce this work



n.girometti@nhs.net



[@chelwestFT](https://twitter.com/chelwestFT)
[@56deanstreet](https://twitter.com/56deanstreet)